Thieler Law Corp advises investors with losses exceeding $100,000 of the April 25, 2019 lead plaintiff deadline in a class action lawsuit filed against Diplomat Pharmacy Inc (NYSE: DPLO) (“Diplomat” or “the Company”). The suit is pending in the U.S. District Court for the Central District of California and investors, who purchased Diplomat Pharmacy Inc securities between February 26, 2018 and February 21, 2019, have until April 25, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Diplomat Pharmacy Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On February 22, 2019, the Company filed a Form 8-K with the SEC, revealing that it was postponing the release of its Form 10-K for the fiscal year ended December 31, 2018 due to a ''recent determination'' that it would need to record a non-cash impairment charge upwards of approximately $630 million relating to 2017 acquisitions for its pharmacy benefit management business. Furthermore, the Company revealed that it was withdrawing its preliminary 2019 full-year outlook provided in January.

Following this news, NYSE: DPLO fell $7.59 per share, or over 56%, to close at $5.87 per share on February 22, 2019.

If you were negatively impacted by your investment in Diplomat Pharmacy Inc securities between February 26, 2018 and February 21, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185